Forest Laboratories, Inc. (NYSE: FRX) makes branded and generic prescription drugs. Two drugs account for the majority of Forest's total sales: Lexapro, a drug for the treatment of depression, and Namenda, a drug for the treatment of Alzheimer's disease. The patents for both drugs will expire by 2013., meaning FRX has only a few years to replace the revenue generated by these two products.
New products in Forest Laboratories' pipeline include ceftaroline, an injectable antibiotic acquired through the acquisition of Cerexa, Inc. in 2007; linaclotide, a product for the treatment of gastrointestinal disorders developed through a 50/50 co-development and marketing parntnership with Ironwood Pharmaceuticals, Inc.; and aclidinium, a drug for treating respiratory diseases to which Forest has acquired exclusive United States marketing rights through a collaborative agreement with Laboratorios Almirall SA of Spain.
Three companies make up the majority of FRX's purchasers, making FRX dependent on these major buyers. McKesson (MCK), Cardinal Health (CAH), and AmerisourceBergen Corporation (Holding Co) (ABC) made up 36%, 33%, and 20% of FRX's total sales in 2010 respectively. As a result, the loss of any one customer could have huge implications for FRX's revenues.
Forest Laboratories revenues come primarily from the sales of branded products Lexapro and Namenda, as well as various other branded and generic drugs and several over-the-counter products.
FRX has grown its revenues for the past five years. In 2010 (FRX's fiscal year ends March 31 of each year), FRX posted total revenues of $4.19 billion, an increase from its 2009 total revenues of $3.92 billion. However, despite the increase in revenues, FRX's net income actually declined. Between 2009 and 2010, FRX's net income decreased from $768 million in 2009 to $682 million in 2010.
In fiscal 2010, FRX earned 89% of its revenues from four drugs: Lexapro®, Celexa®, Namenda® and Savella®. The patents for both Lexapro and Namenda are set to expire in March 2012, and September, 2013 respectively. If Forest is to remain successful going forward, they will need to develop or license one or more new blockbuster products to make up for the inevitable sales losses to be suffered from the introduction of generics.
Sales of Lexapro have grown steadily, accounting for 17.7% of total antidepressant prescriptions in the SSRI/SNRI (selective serotonin reuptake inhibitor/serotonin-norepinephrine reuptake inhibitor) category. However, the antidepressant market has slowed, while Lexapro has lost some market share to generics of (ironically enough) Forest Laboratory's own Celexa and other SSRI's.
Sales of Forest's Alzheimer's treatment drug Namenda have grown significantly, giving the drug 33.8% of total prescriptions in the Alzheimer's market. This is due largely to its introduction and status as the first FDA approved drug for treatment of moderate-to-late stage Alzheimer's Disease. While Forest Laboratories predicts that sales will continue to grow for the next several years, analysts predict the maturation of the Alzheimer's drug market should continue to slow the rate of growth.
Forest's relatively small size within the pharmaceutical industry makes it particularly susceptible to competition, lacking the financial resources to develop and sell a wide array of products, relying instead on the success of a few key drugs. Some of Forest Laboratories' major competitors include:
|Company||Total Revenues (most recent filing)||R&D Expenditures (most recent filing)||Net Income (most recent filing)|
|Forest Laboratories (FRX)||$3.84 B||$671 MM||$968 MM|
|Pfizer (PFE)||$48.42 B||$8.10 B||$8.14 B|
|Eli Lilly and Co (LLY)||$18.63 B||$3.49 B||$2.95 B|
|Teva Pharmaceuticals (TFE)||$2.82 B||$198 MM||$539 MM|